Feb 8, 2026Dasatinib + Quercetin Senolytic Protocol: Intermittent Dosing, Safety, and Clinical Trial EvidenceThe dasatinib + quercetin (D+Q) combination is the most clinically studied senolytic protocol. Mayo Clinic trials show clearance of senescent cells and functional improvements. Dasatinib is a chemotherapy drug with significant side effects — this is not a casual intervention.
Feb 3, 2026Fisetin as a Senolytic: Zombie Cell Clearance, Mayo Clinic Data, and Dosing EvidenceFisetin is the most potent natural senolytic identified in preclinical studies. The Mayo Clinic demonstrated senescent cell clearance in human adipose tissue. Clinical protocols use intermittent high-dose cycles. Human evidence is early but promising.